Role of serum matrix metalloproteinase-2 and -9 to predict breast cancer progression

Clin Biochem. 2011 Jul;44(10-11):869-72. doi: 10.1016/j.clinbiochem.2011.04.019. Epub 2011 May 4.


Objective: Matrix metalloproteinases (MMPs), particularly MMP-2 and MMP-9, have been reported as putative tumor markers because of their involvement in cancer invasion and metastasis. The aim of our study was to elucidate the possible role of MMP-2 and -9 as serum prognostic biomarker for breast cancer classification and correlate it with the clinicopathological variables.

Design and methods: Our study consisted of 60 females with primary breast cancer, 40 cases of benign breast disease and 60 healthy female volunteers as controls. The serum MMP-2 and -9 levels were quantitatively measured by ELISA technique.

Results: A significantly raised MMP-2 and MMP-9 levels were observed in breast cancer patients. Significant rise in serum MMP-9 concentration was found in patients presenting with metastasis as well as in those cases who presented with a duration of less than 1year. ROC analyses depicted a serum cutoff value of 315ng/mL for MMP-9 to discriminate the breast cancer patients from the control group.

Conclusion: Our results suggest that serum MMP-9 level is a better marker than serum MMP-2 in predicting the breast cancer development and progression.

MeSH terms

  • Breast Neoplasms / blood*
  • Breast Neoplasms / enzymology
  • Breast Neoplasms / pathology*
  • Disease Progression*
  • Female
  • Humans
  • Matrix Metalloproteinase 2 / blood*
  • Matrix Metalloproteinase 9 / blood*
  • ROC Curve


  • MMP2 protein, human
  • Matrix Metalloproteinase 2
  • Matrix Metalloproteinase 9